Working with academic scientists to develop new therapies and medical devices
Work with us
We have opportunities to licence medical technologies, drug discovery programmes and other technologies developed from academic research.
We have dedicated computational chemistry, small molecule drug discovery and therapeutic antibody facilities available to take early stage drug and antibody targets as far as ‘lead’ stage.
In addition, we provide access to collaborations with world-class MRC scientists and to a wide range of research reagents, tools and cell lines.
We have a strong record in commercialisation, including:
- 12 drugs based on MRC IP with marketing approval, including Humira® and Herceptin®
- Involvement in 17 start-up companies, including Cambridge Antibody Technology (CAT) and Celltech
- Licences to more than 20 companies to sell MRC research reagents
About our opportunities
Our opportunities come from scientists based in Medical Research Council-funded Units and Institutes. We offer pharma and biotech companies the chance to access and develop our opportunities to create valuable healthcare products.
Accessing our opportunities
For more information about the opportunities available to you, please follow the links on the left, or Contact Us.
News feed
Barbara Saxty has co-authored a Nature Communications paper entitled An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.
The University of Leicester is recruiting for an MRCT-supported Research Fellow
MRCT are collaborating with the University of Bristol to develop orally available small molecule TrkA antagonists for treatment of chronic intractable pain.
MRC Technology’s Therapeutic Antibody Group and The University of Aberdeen work together on project to develop therapeutic against a novel cancer target, soluble CTLA-4.